Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theravance has closed the sale of underwritten public offering of $172.5 million aggregate principal amount of unsecured 3% convertible subordinated notes due 2015, which includes the full exercise of the underwriters's over-allotment option for $22.5 million aggregate principal amount of notes.
Subscribe to our email newsletter
The notes are convertible into shares of the company’s common stock at an initial conversion rate of 38.6548 shares per $1,000 principal amount of the notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $25.87 per share.
The company received approximately $166.7 million from the sale of the notes after deducting the underwriting discount and estimated offering expenses. The company intends to use the net proceeds from the offering for general corporate purposes. Merrill Lynch & Co. and Goldman, Sachs & Co. acted as joint book-running managers of the public offering.